Related Experiment Video
Updated: May 13, 2026
10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Subconjunctival dexamethasone implant for non-necrotizing scleritis
Heloisa Nascimento1, Maíra França, Luciana Guadalupe García
1Department of Ophthalmology, Paulista School of Medicine, Hospital São Paulo, Federal University of São Paulo, São Paulo, Brazil. helomn@gmail.com.
Journal of Ophthalmic Inflammation and Infection
|March 22, 2013
Summary
A single subconjunctival dexamethasone implant effectively treated non-necrotizing scleritis, with rapid symptom relief and minimal side effects. This localized therapy offers a safe option for managing this ocular condition.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Non-necrotizing anterior scleritis presents a management challenge.
- Subconjunctival dexamethasone implants offer a localized treatment approach.
Purpose of the Study:
- To evaluate the safety and efficacy of a single-dose subconjunctival 0.7 mg dexamethasone implant (Ozurdex®) for non-necrotizing anterior scleritis.
Main Methods:
- Six patients with non-necrotizing anterior scleritis received a subconjunctival dexamethasone implant injection.
- Procedures were performed under topical anesthesia at a slit lamp.
- Patients were monitored for visual acuity, intraocular pressure, and underwent biomicroscopy and fundus exams for up to six months.
Main Results:
- Symptoms resolved by day 7 in all patients, with most symptom-free by day 2.
- The implant remained visible for at least 45 days.
- No ocular hypertension or serious complications occurred, aside from transient subconjunctival hemorrhage.
Conclusions:
- Subconjunctival dexamethasone implant is a safe and effective local therapy for non-necrotizing scleritis.
- Rapid symptom resolution and a favorable safety profile were observed.
